PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Patients May See Improved Outcomes with Ravulizumab

The findings showed that patients treated with ravulizumab demonstrated better adherence and persistence compared to those on other complement inhibitors.

The ADVANTAGE study, a retrospective longitudinal analysis, included data from 783 PNH patients. Participants were treated with one of the following complement inhibitors: ravulizumab (344 patients), eculizumab (342 patients), or pegcetacoplan (97 patients). The average patient age was 44.2 years, and 59.7% were female.

Patients on ravulizumab experienced longer treatment persistence, with a median duration of 48.4 months, compared to 7.6 months for those on eculizumab and 14.6 months for those on pegcetacoplan.

For patients who received ravulizumab for at least 12 months, there was a notable decrease in healthcare resource utilization (HRU). Specifically, all-cause HRU dropped by 24.8% (P <.001), and PNH-related HRU fell by 32.1% (P <.001) in their first year of treatment compared to the previous year.

Ravulizumab also led to significant reductions in mean all-cause hospitalizations by 44.6% (P =.014), outpatient visits by 19.1% (P <.001), and emergency department visits by 39.8% (P =.008). Additionally, PNH-related hospitalizations decreased by 37.8% (P =.044) and outpatient visits by 22.4% (P <.001). However, there was no significant change in emergency department visits (32.7% decrease; P =.170) or blood transfusions (30.7% decrease; P =.277).

The researchers concluded that these real-world data support the advantages of ravulizumab for patients with PNH.

Source: Hematology Advisor